Enlivex Therapeutics Ltd. (ENLV) vs Lucyd, Inc (LUCY)
A side-by-side comparison of Enlivex Therapeutics Ltd. and Lucyd, Inc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ENLV
Enlivex Therapeutics Ltd.
$0.35HealthcareDelayed quote: Oct 6, 2026, 10:49 AM EDT
LUCY
Lucyd, Inc
$0.93HealthcareDelayed quote: Oct 6, 2026, 10:49 AM EDT
Total return — ENLV vs LUCY
growth of $100 · dividends reinvested · last 4yENLV -99.5% (-73.9%/yr)LUCY -99.2% (-70.5%/yr)LUCY compounded faster over this window
ENLV LUCY
ENLV vs LUCY: by the numbers
- •ENLV is the larger company ($6M vs $6M market cap).
- •Both run net losses; ENLV's is the smaller (0.00% vs -225.28% net margin).
Metrics side by side
Valuation
| Metric | ENLV | LUCY |
|---|---|---|
| P/E ratio | 0.00 | N/A |
| P/S ratio | N/A | 1.71 |
| P/B ratio | 0.00 | 0.85 |
Profitability
| Metric | ENLV | LUCY |
|---|---|---|
| Gross margin | 0.00% | 22.79% |
| Operating margin | 0.00% | -319.16% |
| Net margin | 0.00% | -225.28% |
| ROE | 105.35% | -111.42% |
| ROIC | -0.32% | -122.15% |
Growth (annualized)
| Metric | ENLV | LUCY |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 64.52% |
| Total return CAGR (5Y) | -69.81% | N/A |
Go deeper
Dig into the metrics
Enlivex Therapeutics ROELucyd ROEEnlivex Therapeutics operating marginLucyd operating marginEnlivex Therapeutics revenue growthLucyd revenue growthEnlivex Therapeutics free cash flowLucyd free cash flow
Enlivex Therapeutics & Lucyd appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.